Association between Adverse Maternal Clinical Outcomes and Imbalance of Cytokines and Angiogenic Factors in Preterm Preeclampsia

Abstract

Objective Preeclampsia (PE) is a pregnancy-specific syndrome characterized by abnormal levels of cytokines and angiogenic factors, playing a role in the disease development. The present study evaluated whether immunological markers are associated with the gestational age and with the disease severity in preeclamptic women.

Methods Ninety-five women who developed PE were stratified for gestational age as preterm PE (< 37 weeks) and term PE (≥ 37 weeks of gestation) and compared for disease severity as well as plasma concentration of angiogenic factors and cytokines. The concentrations of placental growth factor (PlGF), vascular endothelial growth factor (VEGF), Fms-like soluble tyrosine kinase (sFlt-1) and soluble endoglin (sEng), as well as the cytokines, tumor necrosis factor-α (TNF-α) and interleukin 10 (IL-10), were determined by enzyme-linked immunosorbent assay (ELISA).

Results The comparison between preeclamptic groups showed a higher percentage of severe cases in preterm PE (82.1%) than in term PE (35.9%). Similarly, the concentrations of TNF-α, sFlt-1, and sEng, as well as TNF-α/IL-10 and sFlt-1/PlGF ratios were significantly higher in the preterm PE group. In contrast, concentrations of PlGF, VEGF, and IL-10 were significantly lower in women with preterm PE. Negative correlations between TNF-α and IL-10 (r = 0.5232) and between PlGF and sFlt1 (r = −0.4158) were detected in the preterm PE.

Conclusion In pregnant women with preterm PE, there is an imbalance between immunological markers, with the predominance of anti-angiogenic factors and TNF-α, associated with adverse maternal clinical outcomes.

Resumo

Objetivo A pré-eclâmpsia (PE) é uma síndrome específica da gravidez caracterizada por níveis anormais de citocinas e fatores angiogênicos, que desempenham um papel no desenvolvimento da doença. Este estudo avaliou se os marcadores imunológicos estão associados à idade gestacional e à gravidade da doença em mulheres com pré-eclâmpsia.

Métodos Noventa e cinco mulheres que desenvolveram PE foram estratificadas pela idade gestacional em PE pré-termo (< 37 semanas) e PE a termo (≥ 37 semanas de gestação) e comparadas quanto à gravidade da doença, bem como à concentração plasmática de fatores angiogênicos e citocinas. As concentrações de fator de crescimento placentário (PlGF), fator de crescimento endotelial vascular (VEGF), tirosina quinase solúvel semelhante a Fms (sFlt-1) e endoglina solúvel (sEng), bem como as citocinas, fator de necrose tumoral alfa (TNF- α) e interleucina 10 (IL-10), foram determinados porensaio de imunoabsorção enzimática (ELISA, na sigla em inglês).

Resultados A comparação entre os grupos com pré-eclâmpsia mostrou maior porcentagem de casos graves em PE pré-termo (82,1%) do que em PE a termo (35,9%). Da mesma forma, as concentrações de TNF-α, sFlt-1 e sEng, bem como as razões TNF-α/IL-10 e sFlt-1/PlGF foram significativamente maiores no grupo de PE pré-termo. Em contraste, as concentrações de PlGF, VEGF e IL-10 foram significativamente menores em mulheres com PE pré-termo. Correlações negativas entre TNF-α e IL-10 (r = 0.5232) e entre PlGF e sFlt1 (r = −0.4158) foram detectadas no grupo de PE pré-termo.

Conclusão Em gestantes com PE pré-termo, ocorre um desequilíbrio entre os marcadores imunológicos, com predomínio de fatores antiangiogênicos e TNF-α, associados a desfechos clínicos maternos adversos.

Keywords

angiogenic factors - clinical adverse outcomes - cytokines - preterm preeclampsia - term preeclampsia

Palavras-chave

fatores angiogênicos - desfechos clínicos adversos - citocinas - pré-eclâmpsia pré-termo - pré-eclâmpsia a termo

Contributions

P. R. N., J. C. P. and M. T. S. P.: concept and design of the study, P. R. N., M. R. V., P. R. N., M. L. M. and V. R. R.: Data collection, analysis, and interpretation of data; V. T. M. B., R. A. A. C., P. R. N., M. T. S. P.: writing of the article and critical review of the intellectual content. All authors: final approval of the version to be published.

Publication History

Received: 30 September 2020

Accepted: 21 July 2021

Article published online:
20 October 2021

• References

• 1 American College of Obstetricians and Gynecologists. Clinical Management Guidelines for Obstetrician–Gynecologists. ACOG Practice Bulletin No. 202: gestational hypertension and preeclampsia. Obstet Gynecol 2019; 133 (01) e1-e25 DOI: 10.1097/AOG.0000000000003018.
• 2 Ghulmiyyah L, Sibai B. Maternal mortality from preeclampsia/eclampsia. Semin Perinatol 2012; 36 (01) 56-59 DOI: 10.1053/j.semperi.2011.09.011.
• 3 Tranquilli AL, Dekker G, Magee L. et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens 2014; 4 (02) 97-104 DOI: 10.1016/j.preghy.2014.02.001.
• 4 Mol BWJ, Roberts CT, Thangaratinam S, Magee LA, de Groot CJM, Hofmeyr GJ. Pre-eclampsia. Lancet 2016; 387 (10022): 999-1011 DOI: 10.1016/S0140-6736(15)00070-7.
• 5 Meis PJ, Michielutte R, Peters TJ. et al. Factors associated with preterm birth in Cardiff, Wales. I. Univariable and multivariable analysis. Am J Obstet Gynecol 1995; 173 (02) 590-596 DOI: 10.1016/0002-9378(95)90287-2.
• 6 Odegård RA, Vatten LJ, Nilsen ST, Salvesen KA, Austgulen R. Preeclampsia and fetal growth. Obstet Gynecol 2000; 96 (06) 950-955
• 7 von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy 2003; 22 (02) 143-148 DOI: 10.1081/PRG-120021060.
• 8 Phillips JK, Janowiak M, Badger GJ, Bernstein IM. Evidence for distinct preterm and term phenotypes of preeclampsia. J Matern Fetal Neonatal Med 2010; 23 (07) 622-626 DOI: 10.3109/14767050903258746.
• 9 Chandra I, Sun L. Preterm and term preeclampsia: differences in biochemical parameter and pregnancy outcomes. Postgrad Med 2018; 130 (08) 703-707 DOI: 10.1080/00325481.2018.1527169.
• 10 Chaiworapongsa T, Chaemsaithong P, Yeo L, Romero R. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol 2014; 10 (08) 466-480 DOI: 10.1038/nrneph.2014.102.
• 11 Sircar M, Thadhani R, Karumanchi SA. Pathogenesis of preeclampsia. Curr Opin Nephrol Hypertens 2015; 24 (02) 131-138 DOI: 10.1097/MNH.0000000000000105.
• 12 Levine RJ, Lam C, Qian C. et al; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355 (10) 992-1005 DOI: 10.1056/NEJMoa055352.
• 13 Peraçoli JC, Bannwart-Castro CF, Romao M. et al. High levels of heat shock protein 70 are associated with pro-inflammatory cytokines and may differentiate early- from late-onset preeclampsia. J Reprod Immunol 2013; 100 (02) 129-134 DOI: 10.1016/j.jri.2013.08.003.
• 14 Helmo FR, Lopes AMM, Carneiro ACDM. et al. Angiogenic and antiangiogenic factors in preeclampsia. Pathol Res Pract 2018; 214 (01) 7-14 DOI: 10.1016/j.prp.2017.10.021.
• 15 Umapathy A, Chamley LW, James JL. Reconciling the distinct roles of angiogenic/anti-angiogenic factors in the placenta and maternal circulation of normal and pathological pregnancies. Angiogenesis 2020; 23 (02) 105-117 DOI: 10.1007/s10456-019-09694-w.
• 16 Luppi P, Deloia JA. Monocytes of preeclamptic women spontaneously synthesize pro-inflammatory cytokines. Clin Immunol 2006; 118 (2-3): 268-275 DOI: 10.1016/j.clim.2005.11.001.
• 17 Peraçoli JC, Rudge MV, Peraçoli MT. Tumor necrosis factor-alpha in gestation and puerperium of women with gestational hypertension and pre-eclampsia. Am J Reprod Immunol 2007; 57 (03) 177-185 DOI: 10.1111/j.1600-0897.2006.00455.x.
• 18 Raghupathy R. Cytokines as key players in the pathophysiology of preeclampsia. Med Princ Pract 2013; 22 (Suppl. 01) 8-19 DOI: 10.1159/000354200.
• 19 Aggarwal R, Jain AK, Mittal P, Kohli M, Jawanjal P, Rath G. Association of pro- and anti-inflammatory cytokines in preeclampsia. J Clin Lab Anal 2019; 33 (04) e22834 DOI: 10.1002/jcla.22834.
• 20 Jardim LL, Rios DR, Perucci LO, de Sousa LP, Gomes KB, Dusse LM. Is the imbalance between pro-angiogenic and anti-angiogenic factors associated with preeclampsia?. Clin Chim Acta 2015; 447: 34-38 DOI: 10.1016/j.cca.2015.05.004.
• 21 Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: pathophysiology, challenges, and perspectives. Circ Res 2019; 124 (07) 1094-1112 DOI: 10.1161/CIRCRESAHA.118.313276.
• 22 Liu Z, Afink GB, Dijke PT. Soluble fms-like tyrosine kinase 1 and soluble endoglin are elevated circulating anti-angiogenic factors in pre-eclampsia. Pregnancy Hypertens 2012; 2 (04) 358-367 DOI: 10.1016/j.preghy.2012.06.003.
• 23 Venkatesha S, Toporsian M, Lam C. et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12 (06) 642-649 DOI: 10.1038/nm1429.
• 24 Rana S, Powe CE, Salahuddin S. et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012; 125 (07) 911-919 DOI: 10.1161/CIRCULATIONAHA.111.054361.
• 25 De Oliveira L, Peraçoli JC, Peraçoli MT. et al. sFlt-1/PlGF ratio as a prognostic marker of adverse outcomes in women with early-onset preeclampsia. Pregnancy Hypertens 2013; 3 (03) 191-195 DOI: 10.1016/j.preghy.2013.02.003.
• 26 Pinheiro CC, Rayol P, Gozzani L. et al. The relationship of angiogenic factors to maternal and neonatal manifestations of early-onset and late-onset preeclampsia. Prenat Diagn 2014; 34 (11) 1084-1092 DOI: 10.1002/pd.4432.
• 27 Peraçoli MT, Bannwart CF, Cristofalo R. et al. Increased reactive oxygen species and tumor necrosis factor-alpha production by monocytes are associated with elevated levels of uric acid in pre-eclamptic women. Am J Reprod Immunol 2011; 66 (06) 460-467 DOI: 10.1111/j.1600-0897.2011.01016.x.
• 28 Cristofalo R, Bannwart-Castro CF, Magalhães CG. et al. Silibinin attenuates oxidative metabolism and cytokine production by monocytes from preeclamptic women. Free Radic Res 2013; 47 (04) 268-275 DOI: 10.3109/10715762.2013.765951.
• 29 Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation 2010; 122 (05) 478-487 DOI: 10.1161/CIRCULATIONAHA.109.895458.
• 30 Maynard SE, Min JY, Merchan J. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111 (05) 649-658 DOI: 10.1172/JCI17189.
• 31 Rana S, Salahuddin S, Mueller A, Berg AH, Thadhani RI, Karumanchi SA. Angiogenic biomarkers in triage and risk for preeclampsia with severe features. Pregnancy Hypertens 2018; 13: 100-106 DOI: 10.1016/j.preghy.2018.05.008.
• 32 Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 1993; 90 (22) 10705-10709 DOI: 10.1073/pnas.90.22.10705.
• 33 Roberts JM, Rajakumar A. Preeclampsia and soluble fms-like tyrosine kinase 1. J Clin Endocrinol Metab 2009; 94 (07) 2252-2254 DOI: 10.1210/jc.2009-0945.
• 34 Leaños-Miranda A, Méndez-Aguilar F, Ramírez-Valenzuela KL. et al. Circulating angiogenic factors are related to the severity of gestational hypertension and preeclampsia, and their adverse outcomes. Medicine (Baltimore) 2017; 96 (04) e6005 DOI: 10.1097/MD.0000000000006005.
• 35 McCarthy FP, Ryan RM, Chappell LC. Prospective biomarkers in preterm preeclampsia: A review. Pregnancy Hypertens 2018; 14: 72-78 DOI: 10.1016/j.preghy.2018.03.010.